I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

Tucson Symposium 2025

-
Coming soon
03:00 PM
Duration 60mins Arizona, USA
AVENIO Tumor Tissue CGP Automated Assay: End-to-End Solution with High Sample Pass Rate, and High Analytical Sensitivity and Specificity
Megan Fong

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Arizona, USA
AVENIO Tumor Tissue CGP Automated Assay: End-to-End Solution With High Performance on NextSeq 500/550
Vivian Yu

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Arizona, USA
ctDNA-Based MRD Assay for Non-Hodgkin Lymphomas: Applications for Risk Stratification and Disease Monitoring
Corinna Lutterbeck

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Arizona, USA
Roche Digital Pathology Dx whole slide imaging system is comparable to traditional microscopy for primary diagnosis in surgical pathology
Keith A. Wharton

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Arizona, USA
Evaluation of pre analytics and the impact on staining with the ultrasensitive kappa and lambda Dual ISH Assay
Bowdoin Su

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Arizona, USA
An ultrasensitive dual in situ hybridization (ISH) mRNA assay is equivalent in performance to flow cytometry in determination of kappa/lambda (K/L) restriction status in B cell lymphomas and plasma cell malignancies
Sarah Gladden

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 60mins Arizona, USA
Evaluating Navify Mutation Profiler for Use in Tertiary Analysis of Hematologic Malignancies
Michael Clark

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar